Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis

Arthritis and Rheumatism

Volumn 42, Issue 6, 1999, Pages 1128-1139

  Van Meurs, Joyce B J ^a   Van Lent, Peter L E M ^a   Holthuysen, Astrid E M ^a   Singer, Irwin I ^b   Bayne, Ellen K ^b   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; ANTIGEN; COLLAGEN; ENZYME; EPITOPE; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; PROTEOGLYCAN; STROMELYSIN; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARTILAGE CELL; CARTILAGE DEGENERATION; DISEASE MODEL; ENZYME KINETICS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; COLLAGEN; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; EPITOPES; IMMUNOENZYME TECHNIQUES; KNEE JOINT; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; ZYMOSAN;

EID: 0033000529     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2     Document Type: Article

References (40)

1. Fosang AJ, Neame PL, Hardingham TE, Murphy G, Hamilton JA. Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. J Biol Chem 1991;266:15579-82.
2. Fosang AJ, Last K, Knauper V, Neame PJ, Murphy G, Hardingham TE, et al. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J 1993;295:273-6.
3. Flannery CR, Lark MW, Sandy JD. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan: evidence for proteolysis at this site in-vivo in human cartilage. J Biol Chem 1992;267:1008-14.
4. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993;36:1214-22.
5. 374 bond in the interglobular domain. J Clin Invest 1992;89:1512-6.
6. Sandy JD, Neame PJ, Boyton RE, Flannery CR. Catabolism of aggrecan in cartilage explants: identification of a major cleavage site within the interglobular domain. J Biol Chem 1991;266: 8683-5.
7. Lark MW, Gordy JT, Weidner JR, Ayala J, Kimura JH, Williams HR, et al. Cell-mediated catabolism of aggrecan: evidence that cleavage at the 'aggrecanase' site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain. J Biol Chem 1995;270:2550-6.
8. Loulakis P, Shrikhande A, Davis G, Maniglia CA. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures: putative site(s) of enzymatic cleavage. Biochem J 1992;284:589-93.
9. Bottomley KM, Borkakoti N, Bradshaw D, Brown PA, Broadhurst MJ, Budd JM, et al. Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors. Biochem J 1997;323:483-8.
10. Arner EC, Hughes CE, Decicco CP, Tortorella MD. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis Cartilage 1998;6:214-28.
11. Fosang AJ, Last K, Neame PJ, Murphy G, Knauper V, Tschesche H, et al. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular region of cartilage aggrecan. Biochem J 1994;304:347-51.
12. Arner EC, Deciccio CP, Cherney R, Tortorella MD. Cleavage of native cartilage aggrecan by neutrophil collagenase (MMP-8) is distinct from endogenous cleavage by aggrecanase. J Biol Chem 1997;272:9294-9.
13. Buttner FH, Hughes CE, Margerie D, Lichte A, Tschesche H, Caterson B, et al. Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the 'aggrecanase' and the MMP sites: characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan. Biochem J 1998;333:159-65.
14. Tortorella MD, Pratta MA, Fox JW, Arner EC. The interglobular domain of cartilage aggrecan is cleaved by hemorrhagic metalloproteinase HT-d (atrolysin C) at the matrix metalloproteinase and aggrecanase sites. J Biol Chem 1998;273:5846-50.
15. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996;98:2292-9.
16. Singer II, Kawka DW, Bayne EK, Donatelli SA, Weidner JR, Williams HR, et al. VDIPEN, a metalloproteinase-generated neoepitope is induced and immunolocalizes in articular cartilage during inflammatory arthritis. J Clin Invest 1995;95:2178-86.
17. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NL, et al. Aggrecan degradation in human arthritis: evidence for both metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997; 100:93-106.
18. Van den Berg WB, Kruijsen MWM, van de Putte LBA, Zwarts WA. Antigen-induced arthritis and zymosan-induced arthritis in mice: studies on in vivo cartilage proteoglycan synthesis and chondrocyte death. Br J Exp Pathol 1981;62:308-16.
19. Keystone EC, Schorlemmer HU, Pope C, Allison AC. Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement. Arthritis Rheum 1977;20:1396-401.
20. Brackertz D, Mitchell GF, Mackay IR. Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 1977;20:841-50.
21. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146: 857-68.
22. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
23. McLean IW, Nakane PK. Periodate-lysine-paraformaldehyde fixative: a new fixation for immunoelectron microscopy. J Histochem Cytochem 1974;22:1077-83.
24. Lark MW, Williams HR, Hoerrner LA, Weidner JR, Ayala J, Harper CF, et al. Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using a monospecific anti-peptide serum. Biochem J 1995;307:245-52.
25. Singer II, Scott S, Kawka DW, Bayne EK, Weidner JR, Williams HR, et al. Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. Osteoarthritis Cartilage 1997;5: 407-18.
26. Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. Monoclonal antibodies that specifically recognize neoepitope sequences generated by aggrecanase and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem J 1995;305:799-804.
27. Ilic MZ, Mok MT, Williamson OD, Campbell MA, Hughes CE, Handley CJ. Catabolism of aggrecan by explant cultures of human articular cartilage in the presence of retinoic acid. Arch Biochem Biophys 1995;322:22-30.
28. Henderson B, Lewthwaite J. Cytokines and cartilage loss in rheumatoid arthritis and osteoarthritis. Curr Med Lit 1991;10: 3-10.
29. Mort JS, Magny MC, Lee ER. Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. Biochem J 1998;335:491-4.
30. Baici A, Lang A, Horler D, Kissling R, Merlin C. Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage. Ann Rheum Dis 1995;54:289-97.
31. Van Meurs JBJ, van Lent PLEM, Singer II, Bayne EK, van de Loo FAJ, van den Berg WB. Interleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope VDIPEN in antigen-induced arthritis. Arthritis Rheum 1998;41: 647-56.
32. Tschesche H, Knauper V, Kramer S, Michaelis J, Oberhoff R, Reinke H. Latent collagenase and gelatinase from human neutrophils and their activation. Matrix Biol 1992;1 Suppl:245-55.
33. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJP. Stromelysin is an activator of procollagenase: a study with natural and recombinant enzymes. Biochem J 1987;248:265-8.
34. Knauper V, Wilhelm SM, Seperack PK, DeClerck YA, Langley KE, Osthues A, et al. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 1993;295: 581-6.
35. Kozaci LD, Buttle DJ, Hollander AP. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum 1997;40:164-74.
36. Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998;41:110-21.
37. Schalkwijk J, van den Berg WB, van de Putte LB, Joosten LAB. Elastase secreted by activated polymorphonuclear leucocytes causes damage and matrix degradation in intact articular cartilage: escape from inactivation by alpha-1-proteinase inhibitor. Br J Exp Pathol 1987;68:81-8.
38. 2 release from cartilage in organ culture. Arthritis Rheum 1989;32:288-97.
39. Van de Loo AAJ, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurements of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;48:238-45.
40. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.